PATENT CLAIM ANALYSIS

Application Number: 16103830
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "248000"]

Abstract:
Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

Claim (Index 5):
The method of  claim 1 , wherein administering to the patient with the condition comprises administering, to the patient with the condition, the therapeutically effective amount of the compound comprising a 3,3-dimethyl-1-butanol (DMB) analogue comprising at least one of: 2-Ethyl-1-butanol; (2R)-3,3-Dimethyl-1,2-butanediol; (2S)-3,3-Dimethyl-1,2-butanediol; (2S)-4-Methyl-2-pentanol; (2S)-3-Methyl-2-butanol; (2R)-4-Methyl-2-pentanol; (2R)-3-Methyl-2-butanol; (2S)-2-Pentanol; (2S)-2-Methyl-1,4-butanediol; 2-Methyl-2,4-butanediol; Trimethylolpropane; pharmaceutically acceptable forms thereof; and salts thereof.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.58537
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15610145', '14866398', '15366940', '15605437', '13915299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7261180531200847
- 35 USC 102 Novelty (BERT): 0.495639789669303
- Combined Prediction Score: 0.7030702267750065
- Mean Citation Score: 177.96008600000005
- Max Citation Score: 189.16028
- Similarity Product: 120.41028240429878

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test